1
|
Clark RB, Lamppu D, Libertine L, McDonough A, Kumar A, LaRosa G, Rush R, Elbaum D. Discovery of novel 2-((pyridin-3-yloxy)methyl)piperazines as α7 nicotinic acetylcholine receptor modulators for the treatment of inflammatory disorders. J Med Chem 2014; 57:3966-83. [PMID: 24814197 DOI: 10.1021/jm5004599] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Herein we report the design, synthesis, and structure-activity relationships for a new class of α7 nicotinic acetylcholine receptor (nAChR) modulators based on the 2-((pyridin-3-yloxy)methyl)piperazine scaffold. The oxazolo[4,5-b]pyridine, (R)-18, and 4-methoxyphenylurea, (R)-47, were identified as potent and selective modulators of the α7 nAChR with favorable in vitro safety profiles and good oral bioavailability in mouse. Both compounds were shown to significantly inhibit cellular infiltration in a murine model of allergic lung inflammation. Despite the structural and in vivo functional similarities in the compounds, only (R)-18 was shown to be an agonist. Compound (R)-47 demonstrated silent agonist activity. These data support the hypothesis that the anti-inflammatory activity of the α7 nAChR is mediated by a signal transduction pathway that is independent of ion current.
Collapse
Affiliation(s)
- Roger B Clark
- Critical Therapeutics, Inc. , 60 Westview Street, Lexington, Massachusetts 02421, United States
| | | | | | | | | | | | | | | |
Collapse
|
2
|
Byrne M, Tzekov R, Wang Y, Rodgers A, Cardia J, Ford G, Holton K, Pandarinathan L, Lapierre J, Stanney W, Bulock K, Shaw S, Libertine L, Fettes K, Khvorova A, Kaushal S, Pavco P. Novel Hydrophobically Modified Asymmetric RNAi Compounds (sd-rxRNA) Demonstrate Robust Efficacy in the Eye. J Ocul Pharmacol Ther 2013; 29:855-64. [DOI: 10.1089/jop.2013.0148] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Affiliation(s)
- Michael Byrne
- RXi Pharmaceuticals, Corp., Westborough, Massachusetts
| | - Radouil Tzekov
- Department of Ophthalmology, University of Massachusetts Medical School, Worcester, Massachusetts
| | - Yi Wang
- Department of Ophthalmology, University of Massachusetts Medical School, Worcester, Massachusetts
| | | | - James Cardia
- RXi Pharmaceuticals, Corp., Westborough, Massachusetts
| | - Glenna Ford
- RXi Pharmaceuticals, Corp., Westborough, Massachusetts
| | | | | | | | | | - Karen Bulock
- RXi Pharmaceuticals, Corp., Westborough, Massachusetts
| | - Sharon Shaw
- RXi Pharmaceuticals, Corp., Westborough, Massachusetts
| | - Lyn Libertine
- RXi Pharmaceuticals, Corp., Westborough, Massachusetts
| | - Kevin Fettes
- RXi Pharmaceuticals, Corp., Westborough, Massachusetts
| | | | - Shalesh Kaushal
- Department of Ophthalmology, University of Massachusetts Medical School, Worcester, Massachusetts
| | - Pamela Pavco
- RXi Pharmaceuticals, Corp., Westborough, Massachusetts
| |
Collapse
|
3
|
Kamens J, Khvorova A, Pavco P, Rodgers A, Ford G, Bulock K, Smith-Anzures B, Lapierre J, Lam J, Libertine L, Flannery-Rossi K, Metterville J, Byrne M, Czech M, Ostroff G. Delivery to Macrophages and Efficacy of Orally Administered RNAi Compounds (42.27). The Journal of Immunology 2009. [DOI: 10.4049/jimmunol.182.supp.42.27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
Data will be presented on a method for RNAi compound delivery utilizing RNA encapsulated in beta-glucan shells. When orally administered to mice, these encapsulated nucleic acids traverse the intestinal epithelia by an M cell transcytosis mechanism and are then endocytosed by macrophages. Macrophages containing RNAi compounds migrate to sites of inflammation, and the targeted RNA is specifically inhibited by RNA interference. This formulation presents some unique advantages for therapeutic RNAi including oral mode of administration, low dose (ug/kg/day) and specific delivery to immune cells possibly affording safety advantages for some targets. This novel mode of RNA administration can be used to down-regulate target genes involved in multiple inflammatory disease indications.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | - Michael Czech
- 2Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA
| | - Gary Ostroff
- 2Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA
| |
Collapse
|
4
|
Maziarz A, Habgood G, Lampuu D, Elbaum D, LaRosa G, Kumar A, Libertine L. Anti‐Inflammatory Effects of Alpha‐7 Nicotinic Cholinergic Receptor Agonists in Rat Carrageenan‐Induced Paw Edema. FASEB J 2006. [DOI: 10.1096/fasebj.20.5.a1127-d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Alan Maziarz
- Critical Therapeutics, Inc.60 Westview StreetLexingtonMA02421
| | - Greg Habgood
- Critical Therapeutics, Inc.60 Westview StreetLexingtonMA02421
| | - Diana Lampuu
- Critical Therapeutics, Inc.60 Westview StreetLexingtonMA02421
| | - Dan Elbaum
- Critical Therapeutics, Inc.60 Westview StreetLexingtonMA02421
| | - Greg LaRosa
- Critical Therapeutics, Inc.60 Westview StreetLexingtonMA02421
| | - Anjali Kumar
- Critical Therapeutics, Inc.60 Westview StreetLexingtonMA02421
| | - Lyn Libertine
- Critical Therapeutics, Inc.60 Westview StreetLexingtonMA02421
| |
Collapse
|
5
|
Lewis TA, Bayless L, DiPesa AJ, Eckman JB, Gillard M, Libertine L, Scannell RT, Wypij DM, Young MA. 5-Lipoxygenase inhibition by N-hydroxycarbamates in dual-function compounds. Bioorg Med Chem Lett 2005; 15:1083-5. [PMID: 15686917 DOI: 10.1016/j.bmcl.2004.12.023] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2004] [Revised: 12/06/2004] [Accepted: 12/09/2004] [Indexed: 11/24/2022]
Abstract
A series of N-hydroxycarbamates containing a histaminergic H(1) receptor antagonist pharmacophore was synthesized. In vitro assays determined the compounds had both histaminergic binding and 5-lipoxygenase inhibiting activities comparable to the corresponding N-hydroxyurea analog. Animal models demonstrated antihistaminergic and the 5-lipopxygenase inhibitory activity, with the N-hydroxyurea analog having a better overall profile.
Collapse
|
6
|
Lewis TA, Bayless L, Eckman JB, Ellis JL, Grewal G, Libertine L, Marie Nicolas J, Scannell RT, Wels BF, Wenberg K, Wypij DM. 5-lipoxygenase inhibitors with histamine H(1) receptor antagonist activity. Bioorg Med Chem Lett 2004; 14:2265-8. [PMID: 15081022 DOI: 10.1016/j.bmcl.2004.02.005] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2003] [Accepted: 02/02/2004] [Indexed: 11/30/2022]
Abstract
A series of novel compounds with both 5-lipoxygenase (5-LO) inhibitory and histamine H(1) receptor antagonist activity were designed for the treatment of asthma. These dual-function compounds were made by connecting 5-LO and H(1) pharmacophores,N-hydroxyureas and benzhydryl piperazines, respectively. A range of in vitro activities was observed, with the furan analog 10 demonstrating both activities in an animal model. The activities observed were compared to single-function drugs.
Collapse
|
7
|
Lewis TA, Young MA, Arrington MP, Bayless L, Cai X, Collart P, Eckman JB, Ellis JL, Ene DG, Libertine L, Nicolas JM, Scannell RT, Wels BF, Wenberg K, Wypij DM. Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett 2004; 14:5591-4. [PMID: 15482930 DOI: 10.1016/j.bmcl.2004.08.060] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2004] [Revised: 08/25/2004] [Accepted: 08/26/2004] [Indexed: 10/26/2022]
Abstract
A series of compounds possessing both H(1) histamine receptor antagonist and 5-lipoxygenase (5-LO) inhibitory activities was synthesized. The H(1)-binding scaffolds of cetirizine, efletirizine, and loratadine were linked to a lipophilic N-hydroxyurea, the 5-LO inhibiting moiety of zileuton. Both activities were observed in vivo, as was increased CYP3A4 inhibition compared to their respective single-function drugs. Selected analogs in the series were shown to be orally active in guinea pig models.
Collapse
|
8
|
Scannell RT, Arrington MP, Bayless L, Cai X, Eckman JB, Eckert M, Ene DG, Ellis JL, Hussoin S, Latham GM, Lewis TA, Libertine L, Nicolas J, Selig WM, Schwartz CE, Wels BF, Wypij DM, Young MA, Zou D. Novel dual acting molecules possessing 5-lipoxygenase enzyme inhibition and histamine H(1) receptor antagonist properties. Inflamm Res 2004; 53 Suppl 1:S33-4. [PMID: 15054606 DOI: 10.1007/s00011-003-0315-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2003] [Accepted: 01/01/2003] [Indexed: 11/28/2022] Open
Affiliation(s)
- R T Scannell
- UCB Research, Inc., 840 Memorial Drive, Cambridge, MA 02139, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Selig WM, Bayless L, Libertine L, Eckman JB, Wypij DM, Wels BF, Eckert M, Young MA, Nicolas JM, Scannell RT, Ellis JL. UCB 62045: pharmacology of a novel, dual-function anti-inflammatory agent with histamine type 1 receptor antagonist and 5-lipoxygenase inhibitor activity. Chest 2003; 123:371S. [PMID: 12628983 DOI: 10.1378/chest.123.3_suppl.371s] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|